TY - JOUR
T1 - The Risk of Sympathetic Ophthalmia Associated with Open-Globe Injury Management Strategies
T2 - A Meta-analysis
AU - Patterson, Tim J.
AU - Kedzierski, Adam
AU - McKinney, David
AU - Ritson, Jonathan
AU - McLean, Chris
AU - Gu, Weidong
AU - Colyer, Marcus
AU - McClellan, Scott F.
AU - Miller, Sarah C.
AU - Justin, Grant A.
AU - Hoskin, Annette K.
AU - Cavuoto, Kara
AU - Leong, James
AU - Rousselot Ascarza, Andrés
AU - Woreta, Fasika A.
AU - Miller, Kyle E.
AU - Caldwell, Matthew C.
AU - Gensheimer, William G.
AU - Williamson, Tom
AU - Dhawahir-Scala, Felipe
AU - Shah, Peter
AU - Coombes, Andrew
AU - Sundar, Gangadhara
AU - Mazzoli, Robert A.
AU - Woodcock, Malcolm
AU - Watson, Stephanie L.
AU - Kuhn, Ferenc
AU - Halliday, Sophia
AU - Gomes, Renata S.M.
AU - Agrawal, Rupesh
AU - Blanch, Richard J.
N1 - Publisher Copyright:
© 2023 American Academy of Ophthalmology
PY - 2024/5
Y1 - 2024/5
N2 - Topic: Sympathetic ophthalmia (SO) is a sight-threatening granulomatous panuveitis caused by a sensitizing event. Primary enucleation or primary evisceration, versus primary repair, as a risk management strategy after open-globe injury (OGI) remains controversial. Clinical Relevance: This systematic review was conducted to report the incidence of SO after primary repair compared with that of after primary enucleation or primary evisceration. This enabled the reporting of an estimated number needed to treat. Methods: Five journal databases were searched. This review was registered with International Prospective Register of Systematic Reviews (identifier, CRD42021262616). Searches were carried out on June 29, 2021, and were updated on December 10, 2022. Prospective or retrospective studies that reported outcomes (including SO or lack of SO) in a patient population who underwent either primary repair and primary enucleation or primary evisceration were included. A systematic review and meta-analysis were carried out in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Random effects modelling was used to estimate pooled SO rates and absolute risk reduction (ARR). Results: Eight studies reporting SO as an outcome were included in total. The included studies contained 7500 patients and 7635 OGIs. In total, 7620 OGIs met the criteria for inclusion in this analysis; SO developed in 21 patients with OGI. When all included studies were pooled, the estimated SO rate was 0.12% (95% confidence interval [CI], 0.00%–0.25%) after OGI. Of 779 patients who underwent primary enucleation or primary evisceration, no SO cases were reported, resulting in a pooled SO estimate of 0.05% (95% CI, 0.00%–0.21%). For primary repair, the pooled estimate of SO rate was 0.15% (95% CI, 0.00%–0.33%). The ARR using a random effects model was −0.0010 (in favour of eye removal; 95% CI, −0.0031 [in favor of eye removal] to 0.0011 [in favor of primary repair]). Grading of Recommendations, Assessment, Development, and Evaluations analysis highlighted a low certainty of evidence because the included studies were observational, and a risk of bias resulted from missing data. Discussion: Based on the available data, no evidence exists that primary enucleation or primary evisceration reduce the risk of secondary SO. Financial Disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
AB - Topic: Sympathetic ophthalmia (SO) is a sight-threatening granulomatous panuveitis caused by a sensitizing event. Primary enucleation or primary evisceration, versus primary repair, as a risk management strategy after open-globe injury (OGI) remains controversial. Clinical Relevance: This systematic review was conducted to report the incidence of SO after primary repair compared with that of after primary enucleation or primary evisceration. This enabled the reporting of an estimated number needed to treat. Methods: Five journal databases were searched. This review was registered with International Prospective Register of Systematic Reviews (identifier, CRD42021262616). Searches were carried out on June 29, 2021, and were updated on December 10, 2022. Prospective or retrospective studies that reported outcomes (including SO or lack of SO) in a patient population who underwent either primary repair and primary enucleation or primary evisceration were included. A systematic review and meta-analysis were carried out in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Random effects modelling was used to estimate pooled SO rates and absolute risk reduction (ARR). Results: Eight studies reporting SO as an outcome were included in total. The included studies contained 7500 patients and 7635 OGIs. In total, 7620 OGIs met the criteria for inclusion in this analysis; SO developed in 21 patients with OGI. When all included studies were pooled, the estimated SO rate was 0.12% (95% confidence interval [CI], 0.00%–0.25%) after OGI. Of 779 patients who underwent primary enucleation or primary evisceration, no SO cases were reported, resulting in a pooled SO estimate of 0.05% (95% CI, 0.00%–0.21%). For primary repair, the pooled estimate of SO rate was 0.15% (95% CI, 0.00%–0.33%). The ARR using a random effects model was −0.0010 (in favour of eye removal; 95% CI, −0.0031 [in favor of eye removal] to 0.0011 [in favor of primary repair]). Grading of Recommendations, Assessment, Development, and Evaluations analysis highlighted a low certainty of evidence because the included studies were observational, and a risk of bias resulted from missing data. Discussion: Based on the available data, no evidence exists that primary enucleation or primary evisceration reduce the risk of secondary SO. Financial Disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
KW - Epidemiology
KW - Sympathetic ophthalmia
KW - Trauma
KW - Uveitis
UR - http://www.scopus.com/inward/record.url?scp=85184771982&partnerID=8YFLogxK
U2 - 10.1016/j.ophtha.2023.12.006
DO - 10.1016/j.ophtha.2023.12.006
M3 - Review article
C2 - 38086434
AN - SCOPUS:85184771982
SN - 0161-6420
VL - 131
SP - 557
EP - 567
JO - Ophthalmology
JF - Ophthalmology
IS - 5
ER -